Buchumschlag

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world

Fuente: Wiley Open Access

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	Abdel‐Aziz Shaheen, Mayur Brahmania
Format:	Artículo Open Access
Veröffentlicht:	Wiley 2024
Schlagworte:	Alimentary Pharmacology & Therapeutics
Online-Zugang:	Acceder al recurso
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

Editorial: The tsunami of steatotic liver disease in India, the Asia‐Pacific region and the world—Authors' reply
von: Manya Prasad, et al.
Veröffentlicht: (2024)

Editorial: Crystalising the burden of steatotic liver disease—Authors' reply
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people with HIV in the United States
von: Richie Manikat, et al.
Veröffentlicht: (2024)

Editorial: Updated epidemiology of steatotic liver disease in people withHIVin the United States—Authors' reply
von: Samer Gawrieh, et al.
Veröffentlicht: (2024)

Editorial: Using machine learning to predict significant fibrosis in metabolic dysfunction‐associated steatotic liver disease
von: Richie Manikat, et al.
Veröffentlicht: (2024)

Natural history of clinical outcomes and hepatic decompensation in metabolic dysfunction‐associated steatotic liver disease
von: Nabil Noureddin, et al.
Veröffentlicht: (2024)

Prevalence of at‐risk MASH, MetALD and alcohol‐associated steatotic liver disease in the general population
von: Carolin V. Schneider, et al.
Veröffentlicht: (2024)

Cardiometabolic criteria as predictors and treatment targets of liver‐related events and cardiovascular events in metabolic dysfunction‐associated steatotic liver disease
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Long‐term clinical outcomes in steatotic liver disease and incidence of liver‐related events, cardiovascular events and all‐cause mortality
von: Nobuharu Tamaki, et al.
Veröffentlicht: (2024)

Impact of Evolving Evidence on Pharmacological Therapy for Alcohol‐Associated Hepatitis in Alberta: A Population‐Based Study of Practice Trends and MELD ‐Stratified Effectiveness of Corticosteroids
von: Abdel‐Aziz Shaheen, et al.
Veröffentlicht: (2026)

Machine learning improves the prediction of significant fibrosis in Asian patients with metabolic dysfunction‐associated steatotic liver disease – The Gut and Obesity in Asia (GO‐ASIA) Study
von: Nipun Verma, et al.
Veröffentlicht: (2024)

The overlap with metabolic dysfunction‐associated steatotic liver disease negatively affects outcomes of primary biliary cholangitis
von: María Hernández‐Pérez, et al.
Veröffentlicht: (2024)

Metabolic dysfunction‐associated steatotic liver disease and MetALD increases the risk of liver cancer and gastrointestinal cancer: A nationwide cohort study
von: Yewan Park, et al.
Veröffentlicht: (2024)

Systematic review with meta‐analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction‐associated steatotic liver disease
von: Mohamad Jamalinia, et al.
Veröffentlicht: (2024)

Lubiprostone Reduces Fat Content on MRI‐PDFF in Patients With MASLD: A 48‐Week Randomised Controlled Trial
von: Mohamed El‐Kassas, et al.
Veröffentlicht: (2025)

Poor accuracy and sustainability of the first‐step FIB4 EASL pathway for stratifying steatotic liver disease risk in the general population
von: Antonio De Vincentis, et al.
Veröffentlicht: (2024)

Prevalence and risk factors of metabolic dysfunction‐associated steatotic liver disease in south Central Uganda: A cross‐sectional survey
von: Rocio Enriquez, et al.
Veröffentlicht: (2024)

Impacts of glucagon‐like peptide‐1 receptor agonists on the risk of adverse liver outcomes in patients with metabolic dysfunction‐associated steatotic liver disease cirrhosis and type 2 diabetes
von: Mohamed I. Elsaid, et al.
Veröffentlicht: (2024)

Short‐term reduction of dietary gluten improves metabolic‐dysfunction associated steatotic liver disease: A randomised, controlled proof‐of‐concept study
von: Angelo Armandi, et al.
Veröffentlicht: (2024)

Editorial: Paradox of liver fat content in the spectrum of non‐alcoholic fatty liver disease
von: Sung Won Chung, et al.
Veröffentlicht: (2024)

Meta‐Analysis: Prevalence of Eating Disorders in Inflammatory Bowel Disease
von: Quinn Goddard, et al.
Veröffentlicht: (2025)

Editorial: Sounding the alarm—The rising global burden of adolescent and young adult alcohol‐related liver disease
von: Victoria T. Kronsten, et al.
Veröffentlicht: (2024)

Review article: Oesophageal disorders in chronic liver disease
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Letter: Reflections on the significance of myokines in alcohol‐associated liver disease
von: Yaomin Wang, et al.
Veröffentlicht: (2024)

UK guideline on the transition and management of childhood liver diseases in adulthood
von: Deepak Joshi, et al.
Veröffentlicht: (2024)

Letter: Zinc and selenium—Potential biomarkers for chronic liver disease?
von: Zhuo Li, et al.
Veröffentlicht: (2024)

Letter: Optimising public health policies to combat alcohol‐associated liver disease in youth—Addressing key methodological and regional challenges
von: Rui Zhang, et al.
Veröffentlicht: (2024)

Editorial: Muscles at the expense of liver injury. Is it worth it?
von: C. Stephens
Veröffentlicht: (2024)

Global epidemiology of alcohol‐associated liver disease in adolescents and young adults
von: Pojsakorn Danpanichkul, et al.
Veröffentlicht: (2024)

Myokines are associated with progression, course and mortality in alcohol‐associated liver disease
von: Parminder Kaur, et al.
Veröffentlicht: (2024)

Editorial: The future of managing drug induced liver injury
von: Amanda Nicoll
Veröffentlicht: (2024)

Letter: Prioritising osteosarcopenia assessment in the ongoing care of patients with cholestatic liver diseases
von: Ivan Arcari, et al.
Veröffentlicht: (2024)

Prevalence and prognostic value of zinc and selenium deficiency in advanced chronic liver disease
von: Nina Dominik, et al.
Veröffentlicht: (2024)

Letter: The enigma of angiotensin receptor blocker‐associated enteropathy
von: Mustafa Mohamedrashed, et al.
Veröffentlicht: (2024)

Steatotic liver disease‐associated all‐cause/cause‐specific mortality in the United States
von: Donghee Kim, et al.
Veröffentlicht: (2024)

Letter: Potential impact of Helicobacter pylori infection on oesophageal disorders in chronic liver disease
von: Jannis Kountouras, et al.
Veröffentlicht: (2024)

Letter: The Simple Endoscopic Score for Predicting Crohn's Disease Progression—Not as Simple as It Sounds
von: Ziheng Calvin Xu, et al.
Veröffentlicht: (2025)

Editorial: Gastrointestinal symptoms—A world of differences
von: Kevin W. Olden
Veröffentlicht: (2024)

Letter: Potential impact ofHelicobacter pyloriinfection on oesophageal disorders in chronic liver disease—Authors' reply
von: Francisco Idalsoaga, et al.
Veröffentlicht: (2024)

Editorial: Redefining liver health—Personalised approach to assessment of serum ALT in clinical practice
von: Basile Njei, et al.
Veröffentlicht: (2024)